Fabiana Ferrari1, Francesco Arrigoni2, Anna Miccoli2, Sara Mascaretti2, Eva Fascetti2, Giulio Mascaretti2, Antonio Barile2, Carlo Masciocchi2. 1. Dipartimento di Scienze Cliniche Applicate E Biotecnologiche, University of L'Aquila-San Salvatore Hospital, Via Lorenzo Natali, 67100, L'Aquila, Italy. fabianaferrari@hotmail.it. 2. Dipartimento di Scienze Cliniche Applicate E Biotecnologiche, University of L'Aquila-San Salvatore Hospital, Via Lorenzo Natali, 67100, L'Aquila, Italy.
Abstract
PURPOSE: To evaluate the treatment efficacy of uterine adenomyosis using MRgFUS as a mini-invasive therapy. MATERIALS AND METHODS: Twenty-three patients affected by symptomatic uterine adenomyosis (11 focal and 7 diffuse forms), diagnosed using MRI, were included in this study. Eighteen out of 23 were submitted to MRgFUS. All junctional zone more than 12 mm in width were considered to be adenomyosis. Study evaluates the pre-treatment target volume measured prior to the treatment on the CE T1-weighted sequence and the MRgFUS-treated volume (MRgFUS-TV), represented by the volume of the lesion ablated, measured directly by means of the MRgFUS. The treated volume on the CE T1-weighted sequence (CE MRI-TV) was measured immediately after treatment. After 1 year, the junctional zone thickness was measured in order to compare pre- and post-treatment values. The therapeutic plan consisted of a high-energy-grid sonication. Symptomatology was assessed through the UFS-QOL. RESULTS: The pre-treatment target volume mean value was of 59.7 cc; the MRgFUS-TV had a mean value of 44.9 cc, and the mean value of CE MRI-TV, measured immediately after treatment, was of 52.8 cc, with an increase of 13.7%. The 86.5% of the lesion was treated. After 1 year from the treatment, 15/18 (83%) patients showed thickness of the junctional zone <12 mm; 3/18 (17%) had a junctional zone >12 mm. CONCLUSION: MRgFUS is an encouraging mini-invasive treatment for adenomyosis that permits to maintain the integrity of the uterus in a pathology with limited therapeutic possibility.
PURPOSE: To evaluate the treatment efficacy of uterine adenomyosis using MRgFUS as a mini-invasive therapy. MATERIALS AND METHODS: Twenty-three patients affected by symptomatic uterine adenomyosis (11 focal and 7 diffuse forms), diagnosed using MRI, were included in this study. Eighteen out of 23 were submitted to MRgFUS. All junctional zone more than 12 mm in width were considered to be adenomyosis. Study evaluates the pre-treatment target volume measured prior to the treatment on the CE T1-weighted sequence and the MRgFUS-treated volume (MRgFUS-TV), represented by the volume of the lesion ablated, measured directly by means of the MRgFUS. The treated volume on the CE T1-weighted sequence (CE MRI-TV) was measured immediately after treatment. After 1 year, the junctional zone thickness was measured in order to compare pre- and post-treatment values. The therapeutic plan consisted of a high-energy-grid sonication. Symptomatology was assessed through the UFS-QOL. RESULTS: The pre-treatment target volume mean value was of 59.7 cc; the MRgFUS-TV had a mean value of 44.9 cc, and the mean value of CE MRI-TV, measured immediately after treatment, was of 52.8 cc, with an increase of 13.7%. The 86.5% of the lesion was treated. After 1 year from the treatment, 15/18 (83%) patients showed thickness of the junctional zone <12 mm; 3/18 (17%) had a junctional zone >12 mm. CONCLUSION: MRgFUS is an encouraging mini-invasive treatment for adenomyosis that permits to maintain the integrity of the uterus in a pathology with limited therapeutic possibility.
Authors: H E Cline; K Hynynen; R D Watkins; W J Adams; J F Schenck; R H Ettinger; W R Freund; J P Vetro; F A Jolesz Journal: Radiology Date: 1995-03 Impact factor: 11.105
Authors: Reena C Jha; Junko Takahama; Izumi Imaoka; Shahin J Korangy; James B Spies; Cirrelda Cooper; Susan M Ascher Journal: AJR Am J Roentgenol Date: 2003-09 Impact factor: 3.959
Authors: Carlo Masciocchi; Francesco Arrigoni; Fabiana Ferrari; Aldo Victor Giordano; Sonia Iafrate; Ilaria Capretti; Ester Cannizzaro; Alfonso Reginelli; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Luca Brunese; Antonio Barile Journal: Med Oncol Date: 2017-02-24 Impact factor: 3.064
Authors: Antonio Barile; Simone Quarchioni; Federico Bruno; Anna Maria Ierardi; Francesco Arrigoni; Aldo Victor Giordano; Sergio Carducci; Marco Varrassi; Giampaolo Carrafiello; Ferdinando Caranci; Alessandra Splendiani; Ernesto Di Cesare; Carlo Masciocchi Journal: Gland Surg Date: 2018-04
Authors: Federico Bruno; Francesco Arrigoni; Nicola Maggialetti; Raffaele Natella; Alfonso Reginelli; Ernesto Di Cesare; Luca Brunese; Andrea Giovagnoni; Carlo Masciocchi; Alessandra Splendiani; Antonio Barile Journal: Gland Surg Date: 2019-04
Authors: Francesco Arrigoni; Antonio Barile; Luigi Zugaro; Alessandra Splendiani; Ernesto Di Cesare; Ferdinando Caranci; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Alfonso Reginelli; Luca Brunese; Carlo Masciocchi Journal: Med Oncol Date: 2017-02-27 Impact factor: 3.064